Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 354 clinical trials
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

erbb2
HER2
breast cancer
hormone therapy
endocrine therapy
  • 220 views
  • 24 Nov, 2020
  • 1 location
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the

metastasis
primary tumor
breast cancer
  • 157 views
  • 07 Nov, 2020
  • 1 location
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.

trastuzumab
measurable disease
HER2
breast cancer
metastasis
  • 0 views
  • 24 Jun, 2020
  • 1 location
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 35 views
  • 17 Jan, 2021
  • 183 locations
  • 148 views
  • 26 Oct, 2020
  • 35 locations
Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.

kidney function tests
capecitabine
HER2
vinorelbine
metastasis
  • 66 views
  • 05 Oct, 2020
  • 105 locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

  • 50 views
  • 28 Dec, 2020
  • 199 locations
Molecular Evaluation in Metastatic Breast Cancer

Background: Despite that up 90% of patients with early-stage breast cancer receives adjuvant treatment, there are still about 300 patients diagnosed with primary metastatic breast cancer (MBC

immunological adjuvant
metastasis
breast cancer
bone metastases
  • 1 views
  • 08 Nov, 2020
  • 1 location
Genetic Characteristics of Metastatic Breast Cancer Patients

Genomic analysis for metastatic breast cancer(MBC) patients Participant (Inclusion criteria) Patients who diagnosed metastatic/stage IV breast cancer

breast cancer
  • 0 views
  • 10 Feb, 2020
  • 1 location
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of this

carboplatin
stage iv breast cancer
taxane
anthracyclines
  • 22 views
  • 07 Nov, 2020
  • 1 location